Harold E. Cross

Harold E. Cross

Auto-generated profile, based on publicly available information

Harold E. Cross

Affiliation Department of Ophthalmology, University of Arizona College of Medicine, Tucson, Arizona, United States of America

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2017 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MMMartina M A Muggenthaler
Martina M A Muggenthaler
BCBiswajit Chowdhury
Biswajit Chowdhury
SHS Naimul Hasan
S Naimul Hasan
HCHarold E Cross
Harold E Cross
BMBrian Mark
Brian Mark
BCBARRY CHIOZA
BARRY CHIOZA
Orofacial clefting is amongst the most common of birth defects, with both genetic and environmental components. Although numerous studies have been undertaken to investigate the complexities of the genetic etiology of this heterogeneous condition, this factor remains incompletely understood. Here, we describe mutations in the HYAL2 gene as a cause of syndromic orofacial clefting. HYAL2, encoding hyaluronidase 2, degrades extracellular hyaluronan, a critical component of the developing heart and palatal shelf matrix. Transfection assays demonstrated that the gene mutations destabilize the molecule, dramatically reducing HYAL2 protein levels. Consistent with the clinical presentation in affected individuals, investigations of Hyal2-/- mice revealed craniofacial abnormalities, including submucosal cleft palate. In addition, cor triatriatum sinister and hearing loss, identified in a proportion of Hyal2-/- mice, were also found as incompletely penetrant features in affected humans. Taken together our findings identify a new genetic cause of orofacial clefting in humans and mice, and define the first molecular cause of human cor triatriatum sinister, illustrating the fundamental importance of HYAL2 and hyaluronan turnover for normal human and mouse development. Cleft lip and palate (CLP) is one of the most common congenital anomalies worldwide. Most of the time the cause is unknown. Affected individuals have multiple problems including difficulties with feeding and speech and have to undergo several operations to correct the orofacial cleft. We describe mutations in an enzyme involved in the development of the palate and heart (Hyaluronidase 2, HYAL2) as the cause of a syndrome of CLP and a congenital heart anomaly (cor triatriatum sinister, CTS) in families from the Amish community and Northern Saudi Arabia of Arabic ethnicity. Mice who lack this enzyme show similar features. HYAL2 is involved in the metabolism of hyaluronic acid, which is important in many tissues of the body. By illustrating a lack of HYAL2 causes CLP and CTS we have demonstrated the importance of HYAL2 for the normal development of the palate and heart, improving our understanding of the complex mechanisms involved in the pathogenesis of CLP and CTS which may ultimately contribute to the development of novel therapies to treat these congenital anomalies.

20 November 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JFJames Fasham
James Fasham
JLJoseph S. Leslie
Joseph S. Leslie
JHjames Harrison
james Harrison
JDJames Deline
James Deline
KWKatie B. Williams
Katie B. Williams
EBEmma L Baple
Emma L Baple
Many studies have demonstrated the clinical utility and importance of epilepsy gene panel testing to confirm the specific aetiology of disease, enable appropriate therapeutic interventions, and inform accurate family counselling. Previously, SCN9A gene variants, in particular a c.1921A>T p.(Asn641Tyr) substitution, have been identified as a likely autosomal dominant cause of febrile seizures/febrile seizures plus and other monogenic seizure phenotypes indistinguishable from those associated with SCN1A, leading to inclusion of SCN9A on epilepsy gene testing panels. Here we present serendipitous findings of genetic studies that identify the SCN9A c.1921A>T p.(Asn641Tyr) variant at high frequency in the Amish community in the absence of such seizure phenotypes. Together with findings in UK Biobank these data refute an association of SCN9A with epilepsy, which has important clinical diagnostic implications.

27 September 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
ZAZineb Ammous
Zineb Ammous
LRLettie E. Rawlins
Lettie E. Rawlins
HJHannah Jones
Hannah Jones
JLJoseph S. Leslie
Joseph S. Leslie
OWOlivia Wenger
Olivia Wenger
ACAndrew Crosby
Andrew Crosby
SNIP1 (Smad nuclear interacting protein 1) is a widely expressed transcriptional suppressor of the TGF-β signal-transduction pathway which plays a key role in human spliceosome function. Here, we describe extensive genetic studies and clinical findings of a complex inherited neurodevelopmental disorder in 35 individuals associated with aSNIP1NM_024700.4:c.1097A>G, p.(Glu366Gly) variant, present at high frequency in the Amish community. The cardinal clinical features of the condition include hypotonia, global developmental delay, intellectual disability, seizures, and a characteristic craniofacial appearance. Our gene transcript studies in affected individuals define altered gene expression profiles of a number of molecules with well-defined neurodevelopmental and neuropathological roles, potentially explaining clinical outcomes. Together these data confirm thisSNIP1gene variant as a cause of an autosomal recessive complex neurodevelopmental disorder and provide important insight into the molecular roles of SNIP1, which likely explain the cardinal clinical outcomes in affected individuals, defining potential therapeutic avenues for future research.